Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 7680 results

  1. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    23 November 2016
    View recommendations

    Sections for TA288

  2. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA379

  3. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA208

  4. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA209

  5. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA210

  6. Prucalopride for the treatment of chronic constipation in women (TA211)

    Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA211

  7. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA212

  8. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.

    Technology appraisal guidance
    Published
    26 January 2011
    View recommendations

    Sections for TA213

  9. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Last updated
    1 November 2010
    View recommendations

    Sections for TA86

  10. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA813

  11. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    30 September 2020
    View recommendations

    Sections for TA650

  12. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  13. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    22 September 2010
    View recommendations

    Sections for TA200

  14. Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)

    NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.

    Technology appraisal guidance
    Published
    27 October 2010

    Sections for TA206

  15. Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

    NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.

    Technology appraisal guidance
    Published
    27 October 2010

    Sections for TA207